We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
BioLeap Wins GlaxoSmithKline Contract to Design Novel Lead Compounds for Previously Intractable Targets
News

BioLeap Wins GlaxoSmithKline Contract to Design Novel Lead Compounds for Previously Intractable Targets

BioLeap Wins GlaxoSmithKline Contract to Design Novel Lead Compounds for Previously Intractable Targets
News

BioLeap Wins GlaxoSmithKline Contract to Design Novel Lead Compounds for Previously Intractable Targets

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "BioLeap Wins GlaxoSmithKline Contract to Design Novel Lead Compounds for Previously Intractable Targets"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

BioLeap and GSK have entered into an agreement whereby BioLeap will design novel lead compounds for "difficult" drug targets. The targets (not disclosed) are ones for which conventional approaches, like high throughput screening, have failed to yield a viable chemical starting point. Typically these are in areas of high unmet medical need.

BioLeap will use its computational fragment-based drug design platform to conceive compounds de novo that are molecularly tailored to bind to the target. GSK will synthesize and test the compounds in biochemical and cellular assays. The process will iterate until GSK selects a Lead Candidate. The terms of the agreement for services were not disclosed.

David Pompliano, PhD, CEO of BioLeap said, “We are very pleased to be working with GSK to accelerate the discovery of truly novel medicines. BioLeap’s platform reliably predicts the effect of compound modifications on target affinity, thus minimizing unproductive guesswork during drug discovery, and producing a better drug candidate more quickly.”
Advertisement